Valerio Therapeutics Société anonyme (EPA:ALVIO)
France · Delayed Price · Currency is EUR 0.3960
+0.0015 (0.38%)
Oct 23, 2026, 9:25 AM CEST
EPA:ALVIO Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 5.55 | 2.57 | 1.79 | 1.8 | 1.44 | 4.06 |
| 5.55 | 2.57 | 1.79 | 1.8 | 1.44 | 4.06 | |
Revenue Growth | 203.22% | 43.50% | -0.39% | 24.74% | -64.48% | 128.72% |
Cost of Revenue | 1.15 | 0.85 | 0.51 | 0.53 | 0.51 | 0.37 |
Gross Profit | 4.4 | 1.73 | 1.28 | 1.27 | 0.93 | 3.69 |
Selling, General & Admin | 6.64 | 4.68 | 13.95 | 19.57 | 18.02 | 8.12 |
Other Operating Expenses | -0.93 | -3.59 | 0.56 | 0.27 | 0.03 | 0.69 |
Operating Expenses | 7.2 | 2.28 | 17.77 | 20.32 | 18.04 | 9.28 |
Operating Income | -2.8 | -0.55 | -16.49 | -19.05 | -17.11 | -5.58 |
Interest Expense | -0.27 | -0.28 | - | -0.14 | -2.19 | -0.85 |
Interest & Investment Income | 0.09 | 0.09 | 0.48 | 0.17 | 0.14 | 0.01 |
Earnings From Equity Investments | -3.78 | -3.8 | -8.02 | - | - | - |
Other Non Operating Income (Expenses) | 0.04 | -0.1 | -0.31 | -0.07 | -0.5 | 0.15 |
EBT Excluding Unusual Items | -6.72 | -4.64 | -24.34 | -19.09 | -19.67 | -6.28 |
Other Unusual Items | - | - | 0.79 | -1.23 | 0.39 | 0.44 |
Pretax Income | -6.72 | -4.64 | -23.55 | -20.33 | -19.28 | -5.84 |
Income Tax Expense | 0.33 | 0.26 | 0.38 | 0.02 | 0.29 | 0.1 |
Net Income | -7.05 | -4.9 | -23.93 | -20.34 | -19.56 | -5.94 |
Net Income to Common | -7.05 | -4.9 | -23.93 | -20.34 | -19.56 | -5.94 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 499 | 274 | 154 | 135 | 106 | 88 |
Shares Outstanding (Diluted) | 499 | 274 | 154 | 135 | 106 | 88 |
Shares Change | 227.01% | 78.10% | 13.81% | 27.86% | 19.88% | 17.03% |
EPS (Basic) | -0.01 | -0.02 | -0.16 | -0.15 | -0.18 | -0.07 |
EPS (Diluted) | -0.02 | -0.02 | -0.16 | -0.15 | -0.18 | -0.07 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1.86 | 0.52 | -12.78 | -17.57 | -9.93 | -8.71 |
Free Cash Flow Per Share | 0.00 | 0.00 | -0.08 | -0.13 | -0.09 | -0.10 |
Gross Margin | 79.31% | 67.08% | 71.39% | 70.39% | 64.38% | 90.94% |
Operating Margin | -50.41% | -21.38% | -919.69% | -1058.50% | -1185.93% | -137.42% |
Profit Margin | -127.07% | -190.36% | -1334.69% | -1130.22% | -1355.65% | -146.16% |
Free Cash Flow Margin | 33.56% | 20.25% | -712.72% | -976.33% | -688.22% | -214.45% |
EBITDA | 1.23 | 3.45 | -3.9 | -18.92 | -17.04 | -5.54 |
EBITDA Margin | 22.11% | 134.09% | -217.29% | - | - | -136.26% |
D&A For EBITDA | 4.02 | 4 | 12.59 | 0.14 | 0.08 | 0.05 |
EBIT | -2.8 | -0.55 | -16.49 | -19.05 | -17.11 | -5.58 |
EBIT Margin | -50.41% | -21.38% | - | - | - | -137.42% |